Zehna Therapeutics

Zehna Therapeutics is an early stage biotech company developing non-bacteriocidal inhibitors of selected gut-microbial pathways clinically and mechanistically linked with chronic metabolic diseases. Our compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide within the host. High systemic levels of trimethylamine N-oxide have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in large-scale clinical cohort studies. Chronic Kidney Disease (CKD) is our lead indication.